GLP-1 Medications and Muscle Loss: What the Research Says

The Concern Is Legitimate

You lose weight on a GLP-1 medication, step on a scale, and feel great. Then someone mentions that a chunk of that lost weight might be muscle, not fat. Suddenly the number doesn't feel as good.

This concern has gained serious traction. Social media is full of "Ozempic face" and "Ozempic body" discussions, and there's real science behind the worry. When you lose weight rapidly through any method — medication, surgery, dieting — you don't just lose fat. You lose some lean tissue too. The question is how much, whether GLP-1 medications make it worse than other approaches, and what you can do about it.

Let's look at what the data actually says.

How Much Muscle Do You Lose on Semaglutide?

In the STEP clinical trials for semaglutide 2.4 mg, roughly 25–40% of the total weight lost was lean mass (which includes muscle, water, bone mineral content, and organ tissue). The exact percentage varied across studies and measurement methods.

That range sounds alarming until you put it in context.

When people lose weight through caloric restriction alone — no medication, just eating less — the lean mass loss ratio is similar. A meta-analysis of diet-only weight loss interventions found that lean mass typically accounts for about 20–30% of total weight lost, with higher ratios at steeper caloric deficits. Bariatric surgery patients see comparable or worse numbers.

The ratio matters because it tells you whether the drug itself is causing unusual muscle loss or whether you're just seeing the normal physiology of weight loss. The evidence so far points toward the latter.

The SEMALEAN Study: A Closer Look at Muscle Function

The SEMALEAN study, published in Diabetes, Obesity and Metabolism in early 2026, tracked 106 patients on semaglutide 2.4 mg with detailed body composition measurements via DEXA scanning.

The results were more nuanced than headlines suggested. Fat mass dropped by 14% at seven months and 18% at twelve months. Lean mass initially declined by about 3 kg at seven months but then stabilized. It didn't keep falling.

Here's the part that gets overlooked: handgrip strength — a validated measure of functional muscle capacity — actually improved by 4.5 kg at twelve months. The prevalence of sarcopenic obesity (having both excess fat and inadequate muscle function) decreased from 49% at baseline to 33% at one year.

So patients lost some lean mass by weight on the scale, but their muscles actually got stronger. That's a meaningful distinction. Lean mass on a DEXA scan includes water, glycogen, and connective tissue. Losing some of that while improving actual muscle function is arguably a net positive.

Semaglutide vs. Tirzepatide: Body Composition Differences

This is where the comparison gets interesting. Tirzepatide (Mounjaro, Zepbound) is a dual GLP-1/GIP receptor agonist, and its body composition profile differs from semaglutide.

Data from the SURMOUNT trials and head-to-head comparisons show that about 25% of weight lost with tirzepatide consisted of lean mass, compared to roughly 39% with semaglutide 2.4 mg. That's a meaningful gap.

The mechanism may involve the GIP receptor. While GLP-1 primarily affects appetite and gastric emptying, GIP has direct effects on fat tissue metabolism. The dual-agonist approach appears to shift weight loss more toward fat and away from lean tissue. Whether this translates to better long-term outcomes is still being studied, but for patients who are particularly concerned about muscle preservation, it's worth discussing tirzepatide with a provider. Our semaglutide vs. tirzepatide comparison covers the full picture.

What About Retatrutide?

Retatrutide is Eli Lilly's triple agonist (GLP-1/GIP/glucagon receptors) currently in Phase 3 trials. The TRIUMPH-4 trial showed weight loss of up to 28.7%, which is the most aggressive result from any GLP-1 class drug to date.

Body composition data from a Lancet substudy (June 2025) showed lean mass loss in the 25–38% range — roughly in line with other weight loss interventions, including bariatric surgery. The glucagon receptor component is theoretically interesting for body composition because glucagon has some catabolic effects on fat while potentially supporting protein synthesis, but the human data hasn't shown a dramatic lean mass advantage over existing medications.

Retatrutide isn't approved yet. Seven Phase 3 trials are expected to report results through 2026. If body composition is a priority for you, it's a drug worth tracking.

The Bimagrumab Combination: A Glimpse at the Future

The most exciting development for muscle preservation came from the BELIEVE trial, a Phase 2 study published in Nature Medicine in 2026. Researchers combined bimagrumab (an antibody that blocks activin receptors involved in muscle wasting) with semaglutide.

The results were striking. The combination produced 22.1% weight loss, with 92.8% of that weight loss coming from fat mass. For comparison, semaglutide alone resulted in 71.8% of weight loss from fat. Bimagrumab alone actually increased lean mass by 2.5% while still producing 10.8% total weight loss.

This combination isn't available yet — it's still in clinical development. But it demonstrates that the muscle loss problem with GLP-1 medications is solvable with targeted pharmacology. Phase 3 trials are being planned.

Practical Strategies to Preserve Muscle on GLP-1 Medications

You don't need to wait for bimagrumab. There are evidence-backed approaches available right now.

Protein Targets

This is the single most impactful thing you can do. GLP-1 medications suppress appetite, which means total caloric intake drops. If protein drops proportionally, your body has less raw material to maintain muscle tissue.

Current guidance for patients on GLP-1 medications:

• Minimum: 0.6–0.7 grams of protein per pound of body weight daily
• Better: 0.7–1.0 grams per pound, especially if you're resistance training
• Practical example: A 200-pound person should aim for 140–200 grams of protein daily

That's a lot when your appetite is suppressed. Prioritize protein at every meal. If you're struggling to hit targets through food alone, a simple whey or plant-based protein shake can bridge the gap.

A 2024 study found that participants on semaglutide who consumed 1.6 g/kg of protein daily combined with twice-weekly strength training preserved 95% of their lean mass over six months. Those who didn't exercise or track protein lost significantly more.

Resistance Training

Aerobic exercise is great for cardiovascular health, but resistance training is what signals your muscles to stick around during a caloric deficit. Your body breaks down tissue it doesn't need. Strength training tells it that muscle is still in demand.

Specific guidance:

• Frequency: Two to three sessions per week, minimum
• Focus: Compound movements — squats, deadlifts, rows, presses, lunges. These recruit the most muscle mass per exercise.
• Intensity: Moderate to heavy loads. Light weights for high reps are less effective at preserving muscle during caloric restriction than heavier loads for moderate reps (6–12 range).
• Progression: Increase weight or reps over time. The stimulus needs to progress for the adaptation signal to persist.

If you're new to resistance training, starting before or right when you begin a GLP-1 medication gives you the best foundation.

Timing and Distribution

Spread protein across three to four meals rather than loading it all into dinner. Research on muscle protein synthesis shows that distributing intake across the day produces better outcomes than a single large dose.

For patients on GLP-1 medications who find it hard to eat large meals, smaller protein-rich meals every four to five hours can be easier to tolerate than fewer, bigger meals that trigger nausea.

Creatine Monohydrate

This is the most studied and cost-effective supplement for muscle preservation. Five grams daily supports muscle retention during caloric deficits. It's safe, cheap, and well-researched across thousands of studies. Discuss it with your provider, but most will be comfortable with this addition.

When Should You Be Worried About Muscle Loss?

Most healthy adults on GLP-1 medications who eat adequate protein and do some resistance training will be fine. The concern is more acute for:

• Adults over 65: Age-related muscle loss (sarcopenia) is already happening. Adding medication-induced lean mass loss on top of that can create functional problems — difficulty with stairs, balance issues, fall risk.
• People with very high weight loss targets: Losing 20%+ of body weight means more total lean mass loss in absolute terms, even if the ratio stays constant.
• Anyone not exercising or eating very low protein: The combination of heavy caloric restriction, no strength stimulus, and inadequate protein is the worst-case scenario for muscle.

If you're in one of these categories, body composition monitoring (DEXA scanning) and working with a provider who takes lean mass seriously is more important. You can find a provider who integrates body composition assessment into their GLP-1 protocol.

The Bottom Line

GLP-1 medications cause some lean mass loss. So does every other effective weight loss intervention. The ratio of lean-to-fat loss with semaglutide is roughly in line with diet-only approaches, and tirzepatide appears to preserve lean mass somewhat better.

The real variable isn't the drug. It's what you do alongside it. Adequate protein (0.7–1.0 g/lb/day) and consistent resistance training (two to three sessions weekly) are the most effective tools for preserving muscle during medication-assisted weight loss. The SEMALEAN study showed that even without structured exercise protocols, muscle function can actually improve while lean mass numbers drop slightly — because patients are losing dysfunctional tissue and fat infiltration within muscles.

Worry less about the scale composition and more about your functional capacity. Can you carry groceries, climb stairs, get off the floor? If those are improving while the scale goes down, your body composition is moving in the right direction.

Frequently Asked Questions About GLP-1 Medications and Muscle Loss

Does Ozempic cause more muscle loss than dieting alone?

The ratio of lean-to-fat loss on semaglutide (roughly 25–40% lean mass) is comparable to what you see with caloric restriction alone (20–30%), and similar to bariatric surgery outcomes. The drug doesn't appear to selectively target muscle. The lean mass loss is a consequence of the caloric deficit the medication creates through appetite suppression. What matters most is whether you're doing resistance training and eating enough protein to counteract that deficit's effect on muscle tissue.

How much protein should I eat on Ozempic or Wegovy to protect muscle?

Aim for at least 0.7 grams of protein per pound of body weight daily. If you're doing regular resistance training, push that toward 1.0 grams per pound. For a 180-pound person, that means 126 to 180 grams of protein per day. Spread it across three to four meals. A 2024 study showed that patients on semaglutide who hit 1.6 g/kg daily with twice-weekly strength training preserved 95% of their lean mass over six months.

Is tirzepatide better than semaglutide for preserving muscle?

The data suggests yes. In clinical trials, about 25% of weight lost with tirzepatide was lean mass, compared to about 39% with semaglutide. The dual GLP-1/GIP mechanism in tirzepatide appears to shift more of the weight loss toward fat. If muscle preservation is a top priority, it's worth exploring tirzepatide with your provider. See our full comparison guide for more details.

Can resistance training completely prevent muscle loss on GLP-1 drugs?

Not completely, but it makes a dramatic difference. Studies show that combining resistance training with adequate protein intake can preserve the vast majority of lean mass during GLP-1-assisted weight loss. The key is consistency: two to three sessions per week focusing on compound movements at moderate to heavy loads. Starting your training program before or at the same time as your medication is more effective than trying to add it later.

What is "Ozempic face" and is it related to muscle loss?

"Ozempic face" refers to the gaunt, aged facial appearance some people notice after significant weight loss on semaglutide. It's caused by loss of facial fat and subcutaneous volume, not specifically muscle loss. It happens with any rapid, substantial weight loss — it's not unique to GLP-1 medications. Patients who lose 15–20%+ of their body weight are more likely to notice facial volume changes. This is a cosmetic concern rather than a health concern, though some patients find it distressing enough to discuss slower weight loss timelines or facial volume restoration with their provider.

Should older adults avoid GLP-1 medications because of muscle loss risk?

Not necessarily, but the approach should be more cautious. Adults over 65 are already losing muscle mass due to aging (sarcopenia), so adding medication-induced lean mass loss requires more careful management. Providers working with older patients typically emphasize higher protein targets, structured resistance training, and regular body composition monitoring via DEXA scanning. The SEMALEAN study showed that even patients starting with sarcopenic obesity had improved muscle function on semaglutide, which is encouraging. If you're over 65, finding a provider who monitors body composition is especially important.